|Day Low/High||242.96 / 247.66|
|52 Wk Low/High||198.64 / 258.45|
Recently poor sector performance is creating opportunity for long-term investors.
It's always surprising how quickly stocks can reverse for no real reason.
It was a solid, though volatile week for U.S. stocks.
Small-cap biotech names are seeing dramatic, widespread declines, creating a liquidation sale for investors.
How far behind the large-cap indexes the S&P 400 and S&P 600 really are is astounding.
These names are among our favorite Dividend Achievers, those companies with at least a decade of dividend growth.
While cryptocurrencies are indeed an asset class, and they are divisible, they do not serve as a medium of exchange, and remain unproven as a store of value.
In a market with elevated valuations and low yields, we see pharmaceutical stocks as a respite from both.
Doesn't the Fed now have to taper asset purchases simply to avoid becoming an even greater force in these markets?
The Dow Jones Industrial Average is being dragged down by Amgen , Microsoft and Boeing .
With the economy apparently growing robustly, the Fed has to watch how the president's plans play out in terms of the size and scope of deficit spending.
Traders could go long at current levels risking below $240 for now.
Let's review this Archegos drama and some lessons from this fickle market.
The fact is that even if there is some compromise, the next fiscal stimulus package will be closer to $1.9 trillion than $600 billion.
The fears of what would happen from Democratic wins in Georgia's race failed to pan out, aside from tech taking a few hits. Here's what's happening instead and why.
As we enter the new year, there's little time to reflect on RMPIA's strong performance. Now, it's all eyes on the 12 months ahead of us.
From Amazon to Zoom, here are my prognostications and best ideas for the new year.
Let's compare several dividend increases in time for the holidays -- and see who wins the 'derby.'
These names are displaying technical deterioration.
With four consecutive flat quarterly dividends, this pharmaceutical name could be on the verge of another hefty raise.
The average declined in October, but it was less than that hit took by the major indexes.
The 'work from home' or 'economic lockdown' trade is close to being back on.